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P U B L I S H E D B Y E L S E V I E R I N C .LettersBlood Pressure Response
to Exercise in
Hypertensive Subjects
Exposed to High Altitude
and Treatment EffectsAcute exposure to high altitude induces a blood
pressure (BP) rise in healthy humans (1). Arterial
hypertension is associated both with enhanced BP
response to exercise and with increased sympa-
thetic discharge in hypoxic conditions (2,3), which
may increase the risk of adverse consequences in
physically active patients who are exposed to high
altitude; however, there is scant evidence available
about BP in these conditions. We aimed to evaluate
the BP response to exercise in hypertensive sub-
jects acutely exposed to high altitude and to
explore whether an antihypertensive drug treat-
ment maintains its BP-lowering efﬁcacy in this
setting.
In the HIGHCARE-ANDES (HIGH altitude CArdio-
vascular REsearch in the ANDES) study (4), 55 mildly
hypertensive subjects (age 57  8 years; 26 females;
body mass index 28.0  14.5 kg/m2), who were ran-
domized to double-blind placebo or to a ﬁxed-dose
antihypertensive combination treatment based on
an angiotensin-receptor blocker (telmisartan 80 mg)
and a calcium-channel blocker (nifedipine gastroin-
testinal therapeutic system [GITS] 30 mg), performed
a step-incremental cardiopulmonary exercise test
(CPET) on a cycle-ergometer both at sea level after
6 weeks of randomized treatment with placebo or
telmisartan/nifedipine-GITS, and on the second day
of stay at 3,260 m altitude (Huancayo, Peru). Arm BP
was measured noninvasively at rest, during the last
minute of each workload step, and at peak exercise,
always with the same device (auscultatory method)
and always by the same operator blinded to the in-
dividual’s treatment allocation. The ethics commit-
tees of Istituto Auxologico Italiano and Universidad
Peruana Cayetano Heredia approved the study, which
was conducted in accordance with the Declaration
of Helsinki. All subjects gave written informed con-
sent to participate, and the study was registeredin the ClinicalTrials.gov database (NCT01830530).
All statistical analyses have been performed using
linear mixed-effects models with contrasts a posteri-
ori accounting for repeated measurements. The false
discovery rate has been used for multiple post-hoc
comparisons.
CPET interruption occurred because of an ex-
cessive BP elevation 14 of 16 times and was more
frequent in the placebo than in the actively treated
group (10 times vs. 4 times) and at high altitude
than at sea level (10 times vs. 4 times). Suspected
exercise-induced myocardial ischemia (electrocar-
diogram changes or symptomatic angina) was the
reason for interrupting CPET in 2 patients (1 in each
treatment group) at high altitude. Going from sea
level to high altitude, peak oxygen consumption and
workload decreased by 12% and 14%, respectively
(from 25.2  5.0 ml/kg/min to 22.1  3.4 ml/kg/min
and from 130  39 W to 111  30 W; p < 0.001),
without treatment-related differences, likely paral-
leling the known cardiac output decline at high
altitude (5). However, the ventilatory equivalents
for oxygen and carbon dioxide increased at each
exercise step (p < 0.001), indicating chemoreﬂex
activation. At each exercise step up to 120 W, systolic
BP was higher at altitude compared with sea level,
whereas diastolic BP at altitude was higher only at
rest (Figure 1). At peak exercise, BP values did not
show any statistically signiﬁcant difference between
high altitude and sea level. However, given that at
altitude maximal exercise capacity was signiﬁcantly
reduced as compared with sea level, when BP was
expressed as a function of individuals’ peak oxygen
consumption (as a surrogate measure of cardiac
output), the pressor response to peak exercise was
signiﬁcantly greater at high altitude than at sea level
(p < 0.001).
Telmisartan/nifedipine-GITS effectively reduced
BP at rest and throughout the exercise test both at sea
level and at altitude, as compared with placebo
(Figure 1).
In conclusion, mildly hypertensive subjects display
a hypoxia-driven enhanced BP response to exercise
during acute exposure to high altitude, which may
carry some safety concerns, given the increasing
number of individuals being exposed to high al-
titude either for leisure or work worldwide. The
FIGURE 1 Systolic and Diastolic Blood Pressure Responses to Exercise in the Different
Study Conditions and According to Treatment Randomization
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2807combination of a long-acting calcium-channel blocker
and a long-acting angiotensin-receptor blocker turned
out to be safe and effective in reducing such an
enhanced BP response to exercise under hypobaric
hypoxic conditions, without adversely affecting exer-
cise capacity.
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